ライナスバイオ、市場の減速を乗り越え、バリュエーションの回復を背景にシリーズA2で800万ドル追加調達
米ニュージャージー州ノースブランズウィック (ビジネスワイヤ) —...
View ArticleBasgenbio to Present at the BIO International Convention 2023
SEOUL, South Korea Basgenbio Inc., a clinico-genomic cohort data-based R&D company, has announced that the company will be presenting at the BIO International Convention 2023 (BIO USA), which...
View ArticleAGC Biologics新推出的AGCellerate具有高效、价位固定和保证产品数量等功能
西雅图 (美国商业资讯)–全球领先的生物制药合同开发和制造组织(CDMO) AGC Biologics在今天发布AGCellerate,这一新方案旨在为生物制药开发商提供高效的支持IND的GMP材料。AGCellerate保证了固定的时间线、成本和数量,并通过开发,使项目加速进入临床阶段。 该新方案为使用单克隆抗体...
View Articleパース・バイオサイエンシーズが新製品「CRISPR Detect」を発表
米ワシントン州シアトル (ビジネスワイヤ) – パース・バイオサイエンシーズは、シングルセルをプールしたCRISPRのスクリーニングをかつてない規模で実現する「CRISPR Detect」の発売を発表しました。当社はアクセスが容易でスケーラブルなシングルセル・シーケンシング・ソリューションの大手プロバイダーです。...
View ArticleParse Biosciences推出CRISPR Detect
西雅图 (美国商业资讯)–Parse Biosciences是易获取且可扩展的单细胞测序解决方案的领先供应商。该公司今天宣布推出CRISPR Detect,支持以前所未有的规模实现单细胞混合CRISPR筛选。...
View ArticleOliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the first patient has been administered on June 5, in a Phase 1...
View ArticlePHCホールディングス、販売・サービス事業子会社SciMed (Asia) Pte. Ltd.の株式を追加取得し完全子会社化...
東京 (ビジネスワイヤ) — PHCホールディングス株式会社(本社:東京都港区、代表取締役社長CEO:宮﨑 正次、以下「PHCHD」)は、この度、事業子会社であるSciMed (Asia) Pte....
View ArticleSciMed (Asia), Life Science Sales and Service Distributing Subsidiary of PHC...
TOKYO PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director and CEO: Shoji Miyazaki, hereafter PHCHD) announces that it has acquired the remaining 30%...
View ArticleAstellas and Cullgen Enter into Strategic Collaboration and Option Agreement...
TOKYO & SAN DIEGO Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Cullgen Inc. (President and CEO: Ying Luo, Ph.D., “Cullgen”) today announced a research...
View ArticlePHC Holdings Corporation的生命科学销售和服务分销子公司SciMed (Asia)成为全资子公司 —收购扩大了PHC...
东京 (美国商业资讯)–PHC Holdings Corporation(总部:日本东京港区,总裁、代表董事兼首席执行官:Shoji Miyazaki,以下简称“PHCHD”)宣布,公司已经收购旗下子公司SciMed (Asia) Pte....
View ArticleDrug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for...
GUILFORD, Conn. & SHANGHAI, China Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class,...
View ArticleCANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM)...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleDiaCarta Announces the Termination of Business Combination Agreement with...
PLEASANTON, Calif. DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced the termination of its Business Combination Agreement with HH&L Acquisition Co. On June...
View ArticleFirst Distribution Agreement Executed with Sonic Healthcare
BRISBANE, Australia Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly...
View Article与Sonic Healthcare签订首份分销协议
澳大利亚布里斯班 (美国商业资讯)– Microba Life Sciences Limited (ASX: MAP)(以下简称“Microba”)很高兴宣布,通过其全资子公司Douglass Hanly Moir Pathology Pty Ltd,与Sonic Healthcare Limited (ASX:...
View Article豪マイクロバ、ソニック・ヘルスケアと初の販売代理店契約を締結
豪ブリスベン (ビジネスワイヤ) — マイクロバ・ライフサイエンス(ASX:MAP、以下「マイクロバ」)は、ソニック・ヘルスケア(ASX:SHL)および完全子会社のダグラス・ハンリー・モア・パソロジー(Douglass Hanly Moir Pathology Pty Ltd)を介し、...
View ArticleINOVIQ and Promega Announce Global Joint Marketing Agreement for EXO-NET...
MELBOURNE, Australia & MADISON, Wis. INOVIQ Limited (ASX:IIQ) (INOVIQ), an innovative developer of exosome solutions and precision diagnostics, and Promega Corporation (Promega), a global leader...
View ArticlePropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleQihan Biotech Announces NMPA Approval of Investigational New Drug (IND)...
HANGZHOU, China Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ...
View Article